IL316867A - Macrocyclic inhibitors of kras for the treatment of cancer - Google Patents

Macrocyclic inhibitors of kras for the treatment of cancer

Info

Publication number
IL316867A
IL316867A IL316867A IL31686724A IL316867A IL 316867 A IL316867 A IL 316867A IL 316867 A IL316867 A IL 316867A IL 31686724 A IL31686724 A IL 31686724A IL 316867 A IL316867 A IL 316867A
Authority
IL
Israel
Prior art keywords
kras
cancer
treatment
macrocyclic inhibitors
macrocyclic
Prior art date
Application number
IL316867A
Other languages
Hebrew (he)
Inventor
Jianguo Chen
Haixia Liu
Hong Shen
Weixing Zhang
Wei Zhu
Original Assignee
Hoffmann La Roche
Jianguo Chen
Haixia Liu
Hong Shen
Weixing Zhang
Wei Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Jianguo Chen, Haixia Liu, Hong Shen, Weixing Zhang, Wei Zhu filed Critical Hoffmann La Roche
Publication of IL316867A publication Critical patent/IL316867A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL316867A 2022-07-04 2023-07-03 Macrocyclic inhibitors of kras for the treatment of cancer IL316867A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2022103694 2022-07-04
CN2022124638 2022-10-11
CN2023070765 2023-01-05
CN2023087633 2023-04-11
PCT/EP2023/068154 WO2024008610A1 (en) 2022-07-04 2023-07-03 Macrocyclic inhibitors of kras for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL316867A true IL316867A (en) 2025-01-01

Family

ID=87155635

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316867A IL316867A (en) 2022-07-04 2023-07-03 Macrocyclic inhibitors of kras for the treatment of cancer

Country Status (17)

Country Link
US (1) US20250257075A1 (en)
EP (1) EP4551578A1 (en)
JP (1) JP2025522629A (en)
KR (1) KR20250029239A (en)
CN (1) CN119546612A (en)
AR (1) AR129819A1 (en)
AU (1) AU2023303814A1 (en)
CA (1) CA3261042A1 (en)
CL (1) CL2024004085A1 (en)
CO (1) CO2024017733A2 (en)
CR (1) CR20240563A (en)
IL (1) IL316867A (en)
MA (1) MA71370A (en)
MX (1) MX2024015363A (en)
PE (1) PE20250843A1 (en)
TW (1) TW202408507A (en)
WO (1) WO2024008610A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240088A1 (en) 2021-05-05 2024-01-16 Revolution Medicines Inc RAS INHIBITORS
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
PE20252395A1 (en) 2023-02-14 2025-10-10 Hoffmann La Roche TRICYCLIC COMPOUNDS FOR CANCER TREATMENT
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (en) 2023-04-07 2026-02-06 锐新医药公司 Macrocyclic RAS inhibitors
KR20260019479A (en) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Combination therapy for RAS-related diseases or disorders
CN121889155A (en) 2023-08-07 2026-04-17 锐新医药公司 RMC-6291 for the treatment of RAS protein-related diseases or disorders
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026021499A1 (en) * 2024-07-24 2026-01-29 苏州泽璟生物制药股份有限公司 Haloalkylene substituted cycloalkyl or heterocyclic inhibitor, and preparation method therefor and use thereof
TW202615038A (en) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (en) * 2019-11-04 2022-06-02 Revolution Medicines Inc Ras inhibitors.
EP4208261A1 (en) * 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations

Also Published As

Publication number Publication date
WO2024008610A1 (en) 2024-01-11
KR20250029239A (en) 2025-03-04
CA3261042A1 (en) 2024-01-11
MA71370A (en) 2025-04-30
AU2023303814A1 (en) 2024-11-21
EP4551578A1 (en) 2025-05-14
PE20250843A1 (en) 2025-03-21
CN119546612A (en) 2025-02-28
AR129819A1 (en) 2024-10-02
TW202408507A (en) 2024-03-01
CL2024004085A1 (en) 2025-03-21
JP2025522629A (en) 2025-07-15
US20250257075A1 (en) 2025-08-14
CR20240563A (en) 2025-02-14
CO2024017733A2 (en) 2025-01-13
MX2024015363A (en) 2025-03-07

Similar Documents

Publication Publication Date Title
CA3261042A1 (en) Macrocyclic inhibitors of kras for the treatment of cancer
IL316706A (en) Macrocycle compounds for the treatment of cancer
AU2024380740A1 (en) Macrocyclic compounds as kras mutant inhibitors for the treatment of cancer
IL287838A (en) Dosing of kras inhibitor for treatment of cancers
IL308195A (en) Ras inhibitors for the treatment of cancer
ES3065771T3 (en) Substituted oxoisoindoline compounds for the treatment of cancer
IL325744A (en) Combination therapies for the treatment of cancer
IL316829A (en) Menin-mll inhibitors for the treatment of cancer
IL288707A (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
IL304595A (en) Bicyclic tetrahydroazepine derivatives for the treatment of cancer
IL312650A (en) Cdk4 inhibitor for the treatment of cancer
IL321393A (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
IL305780A (en) Methods for the treatment of cancer
IL314687A (en) Treatment of cancer
IL315444A (en) Expression system for the treatment of cancer
CA3294919A1 (en) Omomyc and kras inhibitors combination therapy for the treatment of cancer
GB202508597D0 (en) Compounds for the treatment of cancer
IL318624A (en) Combination therapies for treatment of cancer
EP4452946A4 (en) Compounds for treatment of cancer
HK40061296A (en) Dosing of kras inhibitor for treatment of cancers
HK40084369A (en) Inhibitors of mlh1 and/or pms2 for cancer treatment
GB202311976D0 (en) Treatment of cancer
HK40093971A (en) Smarca4 inhibition for the treatment of cancer
CA3303484A1 (en) Bet inhibitors for the treatment of cancer
GB202218181D0 (en) Treatment of cancer